The anti-tumour efficacy of anti-programmed cell death (anti-PD1) therapy has been demonstrated in a large range of malignant neoplasms, including metastatic melanoma, advanced cutaneous squamous cell carcinoma and lung carcinoma (1). Despite presenting a favourable safety profile, monoclonal antibodies targeting PD-1 are associated with dermatological toxicities, which affect approximately >30% of treated patients (2). These predominantly manifest as eczema-like maculopapular rashes, lichenoid reactions, vitiligo-like lesions, or flares of psoriasis. These cutaneous adverse events generally have an immune aetiology and can, in most cases, be managed and reversed (3, 4). We report here a case of a patient developing eruptive keratoacanthoma (K-A)-like lesions induced by treatment with pembrolizumab, an anti-PD1 monoclonal antibody. Such eruptions represent an unusual cutaneous toxicity, which has, until now, been very rarely reported.

CASE REPORT

An 85-year-old man was treated with pembrolizumab for metastatic bronchial squamous cell carcinoma (SCC). After the second treatment cycle he developed hyperkeratotic nodular lesions (more than 30 lesions in total) on the dorsal region of his hands, knees and legs (Fig. 1). The mucous membranes and scalp were not affected. The patient had no prior history of skin disease. However, he had experienced chronic exposure to ultraviolet (UV) light during outdoor leisure activities. Histopathological analysis of 3 eruptive lesions showed a similar pattern of infiltrative well-differentiated SCCs. Immunostaining identified a predominantly CD3+/CD4+ associated T-lymphocyte infiltrate of the basement membrane, with no lichenoid involvement. Anti-PD1 staining was weakly positive. After clinical-pathological concertation, the lesions were diagnosed as keratoacanthoma-like lesions.

Since an objective regression of the lung cancer was observed, treatment with pembrolizumab was maintained. Clobetasol cream (once per day) was prescribed for topical application to the dorsal region of the hands, knees and legs, and the lesions gradually regressed over a few weeks. Complete regression, without scarring, was noted after 3 months (Fig. 2). At the 6-month follow-up, no recurrence or progression of skin lesions was observed.

DISCUSSION

We report here an additional case of eruptive keratoacanthoma-like eruption induced by pembrolizumab. Anti-PD1 antibodies play a major role in the management of melanoma and locally-advanced or metastatic cutaneous SCCs. The paradoxical development of
eruptive keratoacanthoma-like lesions has been reported recently in 7 patients treated with pembrolizumab, and in 5 patients treated with nivolumab (5–10). Similar to the present case, eruptive keratoacanthoma-like lesions induced by immunotherapy are reported to appear early, between 2 and 18 months after the first infusion. In previously reported cases, the median age of patients was comparable (80 years old) and clinical eruption also presented with multiple violaceous, hyperkeratotic nodules, papules and plaques on the UV-exposed extremities. In the same way, pathology analysis of lesions showed atypical keratinocytes, immune infiltrates composed of CD3+ T cells with scattered CD20 B cells. As observed in our patient, lymphocytes were weakly positive on PD-1 immunostaining. In general, patients were treated with topical clobetasol cream once per day. In addition, 3 patients were also treated with superficial cryotherapy, one patient with 5-fluorouracil intralesional injections, one patient with intralesional steroids, 3 patients were also treated with superficial cryotherapy, and 1 patient with intralesional steroids, 3 patients with curettage and two patients were not given any treatment. The lesions disappeared in a few months. Similarly to previous case reports, we also initiated treatment with topical clobetasol alone, which resulted in significant regression of the K-A-like lesions.

One may hypothesize that anti-PD1 raises an immunological response against sub-clinical epidermal UV-induced dysplasia, resulting in transient epithelial proliferation. This hypothesis is strengthened by the age of patients with more predispositions to cutaneous dysplasia and the location of lesions on UV-exposed areas of the skin. Moreover, we speculate that the mechanism driving the development of secondary skin neoplasms is similar to those observed in tumour pseudo-progression associated with immune checkpoint inhibitors (11). This hypothesis is supported by the fact that, in all patients, the lesions improved with topical steroid therapy, which is not the usual treatment for keratoacanthomas. In addition, pembrolizumab effectively treated the bronchial SCC in our patient. Indeed, cross-reactivity of T cells with tumour epitopes and dysplastic epidermal cells may have participated in the induction of an effective immune reaction in UV-exposed skin, which clinically translated into eruptive keratoacanthomas-like eruption. Finally, pembrolizumab has demonstrated efficacy in the treatment of cutaneous SCCs and the long-lasting clearance of lesions without requiring any additional specific therapeutic procedures, which strongly suggests that pembrolizumab participated in the treatment of the skin lesions. Topical corticosteroids are indicated to control skin inflammatory symptoms. The anti-tumour activity of pembrolizumab may control tumour proliferation, whereas the topical corticosteroids can control the temporary cutaneous inflammation (like oral corticosteroids in the case of other side-effects) (12).

**Conclusion**

The paradoxical eruption of multiple keratoacanthoma-like lesions in UV-exposed areas of the skin seems to be induced by anti-PD-1 therapy. It may be considered as a pseudo-progression of subclinical high-grade intra-epidermal dysplasia. This case may point to the presence of a rare cutaneous side-effect of anti-PD1 receptor antibody therapy that generally resolves spontaneously, allowing for anti-PD-1 treatment to be maintained and the skin lesions to be treated with minimally invasive therapeutic approach.

**REFERENCES**

1. Freshwater T, Kondic A, Ahamadi M, Li CH, de Grief R, de Alwis D and al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer 2017 May 16; 5: 43.
2. Boada A, Carrera C, Segura S, Collgros H, Pasquali P, Bodet D, et al. Cutaneous toxicities of new treatments for melanoma, Clin Transl Oncol 2018; 20: 1373–1384.
3. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19: 345–361.
4. de Golan E, Kwong BY, Swetter SM, Pugliese SB. Cutaneous complications of targeted melanoma therapy. Curr Treat Options Oncol 2016; 17: 57.
5. Bednarek R, Marks K, Lin G. Eruptive keratoacanthomas secondary to nivolumab immunotherapy, Int J Dermatol 2018; 57: 28–29.
6. Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol 2017; 153: 694–697.
7. Chaudhari S, Leon A, Levin E, Neuhaus I, Liao W. Case report of multiple keratoacanthomas and squamous cell carcinomas in a patient receiving pembrolizumab. J Drugs Dermatol 2017; 16: 513–515.
8. Feldstein SI, Patel F, Larsen L, Kim E, Hwang S, Fung MA. Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after programmed cell death 1 inhibition with nivolumab. J Eur Acad Dermatol Venereol 2018; 32: 58–59.
9. Bandino JP, Perry DM, Clarke CE, Marchell RM, Elston DM. Two cases of anti-programmed cell death 1-associated bulous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology. J Eur Acad Dermatol Venereol 2017; 31: 378–380.
10. Taku Fujimura CL, Akira Tsukada YS, Yumi Kambayashi SA. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab. J Dermatol 2018; 46: 177–178.
11. Champiat S, Dercle L, Ammar S, Massard C, Hollebecque A, Postel-Vinay S, et al., Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/ PD-L1. Clin Cancer Res 2017; 23: 1920–1928.
12. Maubec E, Boubaye M, Petrow P, Basset-Seguin N, Grob J, Dreno B. Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial. J Clin Oncol 2019; 36: suppl. 15: 9534.